OR WAIT null SECS
Interim Data Support TECNIS Odyssey IOL Performance, With Alex Hacopian, MD
A study reveals Johnson & Johnson’s TECNIS Odyssey IOL offers excellent vision for presbyopia, with minimal dysphotopsia bothersomeness reported by patients.
Interim results from a single-center study show promising outcomes for Johnson & Johnson’s TECNIS Odyssey intraocular lens (IOL) for presbyopia, with patients reporting excellent vision across distances and minimal bothersomeness of dysphotopsias.
Presented at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, most patients reported little or no reliance on glasses, and 90% rated their vision as “Excellent” or “Very good.” Although some experienced glare, halos, or rings at night, few found them significantly bothersome.
“I used to say three weeks to three months, you’d be over the halos. Now, to cover myself, I say six weeks to six months,” Alex Hacopian, MD, a cataract and refractive surgeon at Mann Eye Institute, told HCPLive. “If we set those reasonable expectations, the ability for patients, even in low light situations, to read up close and see things in the distance, gives this lens the premier spot in my list when I’m choosing a presbyopia-correcting IOL.”
In the single-center, ambispective study investigating visual outcomes after bilateral cataract surgery and TECNIS Odyssey implantation, a total of 80 eyes from 40 subjects were targeted for analysis. Participants were evaluated for ≥3 months postoperatively at a single visit, with clinical evaluations including visual acuities at distance, intermediate, and near.
Hacopian and colleagues also pursued the administration of the assessment of intraocular lens implant symptoms (AIOLIS) and ocular surface disease index (OSDI) questionnaires for this population. At the time of reporting at ASCRS 2025, investigators indicated that 19 patients completed the study.
Upon analysis, binocular mean uncorrected visual acuities at 6 m, 66 cm, 40 cm, and 33 cm were -0.05 ± 0.06, 0.02 ± 0.12, 0.04 ± 0.10, and -0.02 ± 0.07 logMAR, respectively. Dysphotopsias most commonly reported included glare at night, halos, and rings, with 26%, 21%, and 16% of participants, respectively, experiencing them “Always.”
Notably, only 11%, 0%, and 5% of participants were “Extremely” bothered by glare at night, halos, and rings, respectively. Approximately 85% of participants reported needing glasses “Not at all” or “A little of the time,” while 90% rated overall vision as “Excellent.”
Hacopian emphasized the importance of preoperative ocular surface optimization, noting that addressing issues like dry eye and blepharitis before surgery can lead to better measurements, data, and ultimately outcomes from the formulas predicting the refractive power of the implant.
“If we can optimize the ocular surface on the front end, we're going to give the patients a better outcome and we’ll have a better reputation within the community,” Hacopian told HCPLive. “They'll be more satisfied, and we'll feel better for it.”
Hacopian reports disclosures with Allergan and others.
